The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing ...

编者按：2026年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会（ASCO-GU）盛大召开，前列腺癌领域迎来术语体系革新、多项重磅研究数据更新与治疗格局的迭代升级。会议期间，肿瘤瞭望-泌尿时讯特邀美国威尔康奈尔医学院Scott T.

Prostate cancer progression is slashed by PSMA radiation therapy, delaying harsh hormone treatment and protecting well-being ...

Read more about how low testosterone levels are linked to ‘extreme’ disease progression in patients with prostate cancer ...

Based on the efficacy and safety data, Oric will advance the 400mg therapy to Phase III trials, with more treatment-emergent ...

Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...

Prostate cancer affects one in five Australian men, making it the most common cancer in the country. Now, researchers at the ...

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

ORIC Pharmaceuticals (ORIC) lost ~22% in extended trading after the company reported data from a Phase 1b trial for its ...